Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model

References

• Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St Martin TB, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64:7857 - 66; http://dx.doi.org/10.1158/0008-5472.CAN-04-1976; PMID: 15520192
   PubMed Web of Science ®Google Scholar
• Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67:1757 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-06-3700; PMID: 17308118
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos R, Liotta LA, Gimotty PA, Coukos G. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007; 25:852 - 61; http://dx.doi.org/10.1200/JCO.2006.08.8583; PMID: 17327606
   PubMed Web of Science ®Google Scholar
• St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, et al. Genes expressed in human tumor endothelium. Science 2000; 289:1197 - 202; http://dx.doi.org/10.1126/science.289.5482.1197; PMID: 10947988
   PubMed Web of Science ®Google Scholar
• Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, Reynolds E, Tanner C, Moore DT, Gabrielli F, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol 2008; 172:1381 - 90; http://dx.doi.org/10.2353/ajpath.2008.070988; PMID: 18403594
   PubMed Web of Science ®Google Scholar
• Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004; 165:601 - 8; http://dx.doi.org/10.1016/S0002-9440(10)63324-X; PMID: 15277233
   PubMed Web of Science ®Google Scholar
• Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011; 29:325 - 37; http://dx.doi.org/10.3109/07357907.2011.554476; PMID: 21469981
   PubMed Web of Science ®Google Scholar
• Mulder K, Scarfe A, Chua N, Spratlin J. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opin Biol Ther 2011; 11:405 - 13; http://dx.doi.org/10.1517/14712598.2011.557657; PMID: 21281258
   PubMed Web of Science ®Google Scholar
• Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. Dis Markers 2007; 23:419 - 31; http://dx.doi.org/10.1155/2007/257602; PMID: 18057525
   PubMed Web of Science ®Google Scholar
• Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hu G, Schmieder AH, Wickline SA. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 2010; 13:189 - 202; http://dx.doi.org/10.1007/s10456-010-9166-0; PMID: 20411320
   PubMed Web of Science ®Google Scholar
• Street JM, Dear JW. The application of mass-spectrometry-based protein biomarker discovery to theragnostics. Br J Clin Pharmacol 2010; 69:367 - 78; http://dx.doi.org/10.1111/j.1365-2125.2009.03610.x; PMID: 20406221
   PubMed Web of Science ®Google Scholar
• van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007; 12:1379 - 89; http://dx.doi.org/10.1634/theoncologist.12-12-1379; PMID: 18165614
   PubMed Web of Science ®Google Scholar
• Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8:304 - 10; http://dx.doi.org/10.1016/S1470-2045(07)70044-X; PMID: 17395103
   PubMed Web of Science ®Google Scholar
• Becker R, Lenter MC, Vollkommer T, Boos AM, Pfaff D, Augustin HG, Christian S. Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J 2008; 22:3059 - 67; http://dx.doi.org/10.1096/fj.07-101386; PMID: 18490383
   PubMed Web of Science ®Google Scholar
• Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, Sass P, Nicolaides NC, Grasso L, Zhou Y. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci U S A 2007; 104:17965 - 70; http://dx.doi.org/10.1073/pnas.0705647104; PMID: 17986615
   PubMed Web of Science ®Google Scholar
• Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-Chesa P, Park JE, Rettig WJ, Lenter MC. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001; 276:7408 - 14; http://dx.doi.org/10.1074/jbc.M009604200; PMID: 11084048
   PubMed Web of Science ®Google Scholar
• Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A 1992; 89:10832 - 6; http://dx.doi.org/10.1073/pnas.89.22.10832; PMID: 1438285
   PubMed Web of Science ®Google Scholar
• Christian S, Winkler R, Helfrich I, Boos AM, Besemfelder E, Schadendorf D, Augustin HG. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Am J Pathol 2008; 172:486 - 94; http://dx.doi.org/10.2353/ajpath.2008.070623; PMID: 18187565
   PubMed Web of Science ®Google Scholar
• Brady J, Neal J, Sadakar N, Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol 2004; 63:1274 - 83; PMID: 15624764
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Sasaroli D, O’brien-Jenkins A, Botbyl J, Conejo-Garcia JR, Benencia F, Liotta LA, Gimotty PA, Coukos G. Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol Ther 2006; 5:635 - 42; http://dx.doi.org/10.4161/cbt.5.6.2676; PMID: 16627987
   PubMed Web of Science ®Google Scholar
• Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436 - 46; http://dx.doi.org/10.1038/nrc1627; PMID: 15928674
   PubMed Web of Science ®Google Scholar
• Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61:6649 - 55; PMID: 11559528
   PubMed Web of Science ®Google Scholar
• Walter-Yohrling J, Morgenbesser S, Rouleau C, Bagley R, Callahan M, Weber W, Teicher BA. Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res 2004; 10:2179 - 89; http://dx.doi.org/10.1158/1078-0432.CCR-03-1013; PMID: 15041739
   PubMed Web of Science ®Google Scholar
• Bagley RG, Rouleau C, St Martin T, Boutin P, Weber W, Ruzek M, Honma N, Nacht M, Shankara S, Kataoka S, et al. Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther 2008; 7:2536 - 46; http://dx.doi.org/10.1158/1535-7163.MCT-08-0050; PMID: 18723498
   PubMed Web of Science ®Google Scholar
• Simonavicius N, Robertson D, Bax DA, Jones C, Huijbers IJ, Isacke CM. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 2008; 21:308 - 15; http://dx.doi.org/10.1038/modpathol.3801006; PMID: 18192970
   PubMed Web of Science ®Google Scholar
• Wesseling P, Schlingemann RO, Rietveld FJ, Link M, Burger PC, Ruiter DJ. Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study. J Neuropathol Exp Neurol 1995; 54:304 - 10; http://dx.doi.org/10.1097/00005072-199505000-00003; PMID: 7745429
   PubMed Web of Science ®Google Scholar
• MacFadyen JR, Haworth O, Roberston D, Hardie D, Webster MT, Morris HR, Panico M, Sutton-Smith M, Dell A, van der Geer P, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 2005; 579:2569 - 75; http://dx.doi.org/10.1016/j.febslet.2005.03.071; PMID: 15862292
   PubMed Web of Science ®Google Scholar
• Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG. Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis 2004; 21:31 - 7; http://dx.doi.org/10.1023/B:CLIN.0000017168.83616.d0; PMID: 15065600
   PubMed Web of Science ®Google Scholar
• Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, Vogelstein B, St Croix B, Kinzler KW, Huso DL. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci U S A 2006; 103:3351 - 6; http://dx.doi.org/10.1073/pnas.0511306103; PMID: 16492758
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, Coukos G. Vascular leukocytes contribute to tumor vascularization. Blood 2005; 105:679 - 81; http://dx.doi.org/10.1182/blood-2004-05-1906; PMID: 15358628
   PubMed Web of Science ®Google Scholar
• Rettig WJ. Immunogenetics of cell surface antigens of human cancer. Curr Opin Immunol 1992; 4:630 - 40; http://dx.doi.org/10.1016/0952-7915(92)90039-H; PMID: 1418731
   PubMed Web of Science ®Google Scholar
• Zhou Y, Grasso L, Tomkowicz B, Ebel W, Routhier E, Phillips MD, Sass P, Old L, Nicolaides NC. Targeting endosialin/TEM1 as a novel anti-angiogenic agent for the treatment of neovascular disease and cancer. AACR poster 2008;http://www.morphotek.com/CorporateSite/media/Posters/Preclinical-MORAb-004-Study.pdf.
   Google Scholar
• Hasegawa K, Pham L, O’Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006; 12:1868 - 75; http://dx.doi.org/10.1158/1078-0432.CCR-05-1803; PMID: 16551872
   PubMed Web of Science ®Google Scholar
• Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci U S A 1988; 85:4852 - 6; http://dx.doi.org/10.1073/pnas.85.13.4852; PMID: 3387441
   PubMed Web of Science ®Google Scholar
• Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr.. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72:77 - 89; http://dx.doi.org/10.1016/0022-1759(84)90435-6; PMID: 6086763
   PubMed Web of Science ®Google Scholar
• Rouleau C, Curiel M, Weber W, Smale R, Kurtzberg L, Mascarello J, Berger C, Wallar G, Bagley R, Honma N, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res 2008; 14:7223 - 36; http://dx.doi.org/10.1158/1078-0432.CCR-08-0499; PMID: 19010839
   PubMed Web of Science ®Google Scholar
• Pryma DA, O’Donoghue JA, Humm JL, Jungbluth AA, Old LJ, Larson SM, Divgi CR. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med 2011; 52:535 - 40; http://dx.doi.org/10.2967/jnumed.110.083295; PMID: 21421715
   PubMed Web of Science ®Google Scholar
• O’Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, et al. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med 2011; 52:1878 - 85; http://dx.doi.org/10.2967/jnumed.111.095596; PMID: 22068895
   PubMed Web of Science ®Google Scholar
• Chacko AM, Nayak M, Greineder CF, Delisser HM, Muzykantov VR. Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting. PLoS One 2012; 7:e34958; http://dx.doi.org/10.1371/journal.pone.0034958; PMID: 22514693
   PubMed Web of Science ®Google Scholar